|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours:a phase 1 dose-escalation trial 显示文摘 | Falchook GS Long GV Kurzrock R | 2012 | Lancet2012，379，9829： | 1 |
| 2 | Nivolumab in previously untreated melanoma without BRAF rnutation显示文摘 | Robert C Long GV Brady B | 2015 | N EnglJ IVied2015，372，4： | 1 |
| 3 | Pembrolizum- ab versus ipilimumab in advanced melanoma 显示文摘 | Robert C Schachter J Long GV | 2015 | N Engl J Med2015，372，26： | 1 |
| 4 | Partial oxidation ('aging') and surface modification decrease the toxicity of nanosizedzerovalent iron 显示文摘 | Phenrat T Long TC Lowry GV | 2008 | Environ Sci Technol2008，43，： | 1 |
| 5 | Nivolumab in Previously Untreated Melanoma without BRAF Mutation显示文摘 | Robert C Long GV Brady B | 2014 | N Engl J Med2014，372，4： | 1 |
| 6 | COMBId A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinih to dabrafenib and trametinib placebo as firs'I' -line therapy in patients (pts) with unresectable or metastatic BRAFv600E/K mutation-positive cutaneous melanoma显示文摘 | LONG GV STROY AKOVSKY DL GOGAS H | 2014 | J Clin Oncol2014，32，5： | 1 |
| 7 | Pembrolizumab versus ipilimumab in advanced melanoma显示文摘 | Robert C Sehaehter J Long GV | 2015 | N Engl J Med2015，372，26： | 1 |
| 8 | Dabrafenib in patients with melanoma,untreated brain metastases,and other solid tumours:a phase 1 dose-escalation trial显示文摘 | Falchook GS Long GV Kurzrock R | | 0，，9829： | 1 |
| 9 | Dabrafenib in patients with melanoma, untreated brain metastases, and other solid turnouts: a phase 1 dose-escalation trial显示文摘 | Falchook GS Long GV Kurzrock R | 2012 | Lancet2012，379，9829： | 1 |
| 10 | Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma显示文摘 | Long GV Menzies AM Nagrial AM | 2011 | J Clin Oncol2011，29，10： | 1 |
| 11 | Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial显示文摘 | Falehook GS Long GV Kurzroek R | 2012 | Lancet2012，379，53： | 1 |
| 12 | Diagnosis and treatment of KIT-mutant metastatic melanoma 显示文摘 | Lyle M Long GV | 2013 | J Clin Oncol2013，31，26： | 1 |
| 13 | Nivolumab in previ- ously untreated melanoma without BRAF mutation显示文摘 | Robert C Long GV Brady B | 2015 | N Engl J Med2015，372，4： | 1 |
| 14 | Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial 显示文摘 | Falehook GS Long GV Kurzroek R | 2012 | Lancet2012，379，9829： | 1 |
| 15 | Nivolumab improved surviv-al vs dacarbazine in patients with untreated advanced melanoma显示文摘 | Long GV Atkinson V Ascierto PA ei al | 2015 | JTVww/Merf2015，13，： | 1 |
| 16 | Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma显示文摘 | Wilmott JS Long GV Howle JR | 2012 | Clin Cancer Res2012，18，5： | 1 |
| 17 | Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma 显示文摘 | Long GV Stroyakovskiy D Gogas H | 2014 | N Engl J Med2014，371，20： | 1 |
| 18 | Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial 显示文摘 | Falchook GS Long GV Kurzrock R | 2012 | Lancet2012，379，9829： | 1 |
| 19 | Nivolumab in previously untreated melanoma without BRAF mutation显示文摘 | Robert C Long GV Brady B | 2015 | N Engl J Med2015，372，4： | 1 |
| 20 | Pembrolizumab versus ipilimttmab in advanced melanoma 显示文摘 | Robert C Schachter J Long GV | 2015 | N Engl J Med2015，372，26： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员